Nyxoah S.A. (NASDAQ:NYXH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Nyxoah S.A. (NASDAQ:NYXH) have received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $20.60.

Several research analysts have recently commented on NYXH shares. Stifel Nicolaus raised their price objective on Nyxoah from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. Oppenheimer raised their target price on shares of Nyxoah from $17.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, March 14th. Cantor Fitzgerald upped their price target on shares of Nyxoah from $10.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, February 9th. Piper Sandler increased their price objective on shares of Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Finally, HC Wainwright restated a “buy” rating and set a $22.00 target price (up previously from $18.00) on shares of Nyxoah in a research note on Wednesday, March 20th.

Nyxoah Stock Down 7.5 %

Shares of NYXH stock opened at $9.03 on Tuesday. The company has a current ratio of 4.73, a quick ratio of 4.50 and a debt-to-equity ratio of 0.12. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00. The stock has a market cap of $225.21 million, a P/E ratio of -5.38 and a beta of 1.58. The company has a 50 day simple moving average of $12.92 and a two-hundred day simple moving average of $8.91.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). Nyxoah had a negative return on equity of 38.58% and a negative net margin of 993.28%. The firm had revenue of $1.96 million during the quarter, compared to analyst estimates of $2.01 million. On average, research analysts expect that Nyxoah will post -1.78 earnings per share for the current year.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.